Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Down 3.3% – What’s Next?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) fell 3.3% during mid-day trading on Tuesday . The company traded as low as $1.47 and last traded at $1.48. 39,089 shares changed hands during trading, a decline of 19% from the average session volume of 48,092 shares. The stock had previously closed at $1.53.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ACXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen upgraded Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 28th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Acurx Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Down 3.3%

The company’s 50-day moving average price is $2.38 and its 200-day moving average price is $3.91. The firm has a market cap of $3.77 million, a price-to-earnings ratio of -0.17 and a beta of -1.16.

Hedge Funds Weigh In On Acurx Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals during the fourth quarter worth approximately $103,000. Jane Street Group LLC acquired a new stake in Acurx Pharmaceuticals during the 4th quarter worth $27,000. Geode Capital Management LLC purchased a new stake in shares of Acurx Pharmaceuticals during the fourth quarter worth $31,000. Armistice Capital LLC acquired a new stake in shares of Acurx Pharmaceuticals in the second quarter valued at about $551,000. Finally, O Brien Greene & Co. Inc acquired a new stake in shares of Acurx Pharmaceuticals in the second quarter valued at about $31,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).